Patents by Inventor Nobunao Ikewaki

Nobunao Ikewaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?-1.3-1.6 glucan (Aureobasidium medium)
    Patent number: 6956120
    Abstract: Aureobasidium ?-1,3-1,6 glucans and compositions containing such glucans, as well as methods of their preparation. Aureobasidium medium that contains ?-1,3-1,6 glucans, particularly medium produced by Aureobasidium strain FERM P-18099. The ?-glucans of the present invention have a variety of industrial and commercial uses, including applications in pharmaceutical or medical products or treatments, for the removal or control of environmental or microbiological contaminants, in cosmetics, and in nutritional products and foods.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: October 18, 2005
    Inventors: Nobunao Ikewaki, Noboru Fujii, Takashi Onaka
  • Beta-1.3-1.6 glucan (Aureobasidium medium)
    Publication number: 20020082418
    Abstract: Aureobasidium &bgr;-1.3-1.6glucans and compositions containing such glucans, as well as methods of their preparation. Aureobasidium medium that contains &bgr;-1.3-1.6glucans, particularly medium produced by Aureobasidium strain FERM P-18099. The &bgr;-glucans of the present invention have a variety of industrial and commercial uses, including applications in pharmaceutical or medical products or treatments, for the removal or control of environmental or microbiological contaminants, in cosmetics, and in nutritional products and foods.
    Type: Application
    Filed: November 9, 2001
    Publication date: June 27, 2002
    Applicant: Yasushi ONAKA
    Inventors: Nobunao Ikewaki, Noboru Fujii, Takashi Onaka
  • Antibodies produced from lipopolysaccharide-stimulated monocyte/macprophage cell lines
    Patent number: 5677150
    Abstract: Lipopolysaccharide-stimulated monocyte/macrophage cell lines are used as antigens to obtain antibodies. Antibodies which inhibit intercellular adhesion of cells stimulated by a differentiation factor or which induce intercellular aggregation of cells in the process of differentiation under stimulation by a differentiation factor are disclosed. Such antibodies can be used to suppress immune responses and in clinical diagnosis of immune system disorders.
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: October 14, 1997
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Nobunao Ikewaki, Hidetoshi Inoko
  • Process for the formation of human-human hybridoma
    Patent number: 4916072
    Abstract: A human-human hybridoma is formed by subjecting a transformed human cell to a proliferaton inhibitory treatment and then fusing the thus-treated human cell with a human antibody producing cell. A desired clone may be selected from the resultant fused cells by using an anti-HLA antibody.
    Type: Grant
    Filed: March 30, 1987
    Date of Patent: April 10, 1990
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Kimiyoshi Tsuji, Nobunao Ikewaki